Table 3.
Mean (sd) change from week 26 in DTSQ scores (patient-reported outcome analysis population with data in extension phase of trial) to end of week 40 (DTSQs) or end of week 34 (all patients received liraglutide)
| DTSQs | DTSQc | |||||
|---|---|---|---|---|---|---|
| Item | Liraglutide† | Exenatide† | Relative difference between treatments (95% CI; P-value*) | Liraglutide† | Exenatide† | Relative difference between treatments (95% CI; P-value*) |
| Current treatment | ||||||
| Change from week 26 | −0.10 (0.91) (n = 160) | 0.10 (0.95) (n = 134) | −0.20 (−0.42 to 0.02; 0.070) | −0.08 (0.78) (n = 155) | −0.02 (1.14) (n = 131) | −0.06 (−0.29 to 0.17; 0.582) |
| Convenience | ||||||
| Change from week 26 | −0.06 (1.04) (n = 161) | 0.38 (1.39) (n = 136) | −0.47 (−0.75 to −0.19; 0.001) | 0.05 (1.03) (n = 153) | 0.11 (1.55) (n = 131) | −0.08 (−0.40 to 0.23; 0.592) |
| Flexibility | ||||||
| Change from week 26 | −0.07 (1.38) (n = 161) | 0.29 (1.44) (n = 137) | −0.31 (−0.63 to 0.02; 0.064) | −0.02 (1.18) (n = 153) | 0.24 (1.63) (n = 131) | −0.23 (−0.56 to 0.10; 0.173) |
| Understanding | ||||||
| Change from week 26 | 0.09 (0.86) (n = 160) | 0.15 (0.92) (n = 136) | −0.05 (−0.25 to 0.16; 0.660) | −0.04 (1.03) (n = 154) | −0.03 (0.94) (n = 131) | −0.01 (−0.24 to 0.22; 0.921) |
| Recommend | ||||||
| Change from week 26 | 0.01 (0.81) (n = 160) | 0.16 (1.18) (n = 134) | −0.17 (−0.39 to 0.05; 0.138) | −0.04 (1.04) (n = 153) | 0.14 (1.07) (n = 129) | −0.18 (−0.44 to 0.07; 0.160) |
| Continue | ||||||
| Change from week 26 | −0.01 (0.69) (n = 161) | 0.26 (1.22) (n = 135) | −0.29 (−0.51 to −0.06; 0.013) | −0.01 (0.72) (n = 152) | 0.08 (1.36) (n = 129) | −0.09 (−0.35 to 0.17; 0.499) |
| Perceived hyperglycaemia | ||||||
| Change from week 26 | −0.31 (1.60) (n = 160) | −0.50 (1.92) (n = 137) | 0.23 (−0.18 to 0.64; 0.264) | −0.01 (2.14) (n = 154) | −0.44 (1.97) (n = 131) | 0.48 (−0.01 to 0.98; 0.056) |
| Perceived hypoglycaemia | ||||||
| Change from week 26 | −0.21 (1.74) (n = 161) | −0.07 (1.52) (n = 136) | −0.11 (−0.49 to 0.27; 0.582) | −0.07 (2.29) (n = 155) | −0.34 (2.04) (n = 131) | 0.34 (−0.17 to 0.86; 0.191) |
*
Versus week 26 data.
†
Treatment received during the first 26 weeks of the trial.
DTSQc, Diabetes Treatment Satisfaction Questionnaire change version; DTSQs, Diabetes Treatment Satisfaction Questionnaire status version.